雷帕鸣效果怎么样

How effective is Biocon India?

The clinical trial was to study the effectiveness and safety of rapamycin-sirolimus switching treatment regimen, and included 93 patients who were switched to rapamycin-sirolimus-based immunosuppressant therapy after kidney transplantation, including 59 males and 34 females, aged (38±11) years old.

  The treatment plan for all patients adopts a rapid conversion method, that is, calcineurin inhibitors are removed within 2 weeks, and 4 hours after oral administration of cyclospora A or tacrolimus, oral rapamycin (sirolimus tablets) is administered, with a single first loading dose of 6 mg, and then a maintenance dose of 1.0 to 2.0 mg/d. The first sirolimus concentration is measured 5 to 7 days after taking the first dose of sirolimus, and the target mass concentration is 6 to 10 μg/L.

The results showed that after rapamycin conversion treatment, the symptoms of patients with calcineurin inhibitor nephrotoxicity and hepatotoxicity were significantly improved, the blood concentration was maintained at (5.1±1.2) μg/L, the serum creatinine dropped from (297.72±150.28) μmol/L to (123.76±44.2) μmol/L, and the liver function recovered after the conversion. Nine cases of hyperglycemia patients returned to normal and 2 cases improved: 17 cases had a decrease in serum creatinine greater than 25% of the original creatinine level, and the effective rate was 51.5%; 10 cases of tumors occurred 6 to 43 months after kidney transplantation, and 8 cases were stable without recurrence. Three cases of acute rejection occurred within 6 months of rapamycin conversion therapy. The 3-year human renal survival rates after conversion therapy were 90.9% and 75.8% respectively.

It is understood that it has been launched in China, and patients can purchase it at major domestic hospitals or pharmacies with a prescription issued by a doctor. However, the price of the original drug Rapamin is relatively high, which is a big burden for patients who need to take the drug for long-term treatment. Many patients choose India's Biocon Repamin. Biocon India, one of India's top three biotech companies, is an emerging global biopharmaceutical company that is committed to reducing the cost of treatment for chronic diseases such as diabetes, cancer and partners to provide affordable healthcare solutions by leveraging India's cost advantages and autoimmune disease patients and healthcare systems around the world.

Recommended related hot articles: /newsDetail/86905.html